Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
AIM: To investigate the expression level of plasma vascular endothelial growth factor (P-VEGF) in patients with hepatocellular carcinoma (HCC) and its relationship with the clinicopathologic characteristics, and to examine the changes of P-VEGF in the course of transcatheter arterial chemoembolization (TACE). METHODS: Peripheral blood samples were taken from 45 HCC patients before and 1, 3, 7 d, and 1 mo after TACE. Plasma VEGF level was measured with the quantitative sandwich enzyme-linked immunosorbent assay (ELISA). Twenty patients with benign liver lesions and 17 healthy control subjects were also included in this study. RESULTS: Plasma VEGF levels in HCC patients were significantly elevated as compared to those in patients with benign liver lesions (P = 0.006) and in the normal controls (P = 0.003). Significant differences were observed when P-VEGF was categorized by tumor size (P = 0.006), portal vein thrombosis (P = 0.011), distant metastasis (P = 0.017), arterial-portal vein shunting (P = 0.026), and International Union Against Cancer (UICC) TNM stage (P = 0.044). There was no correlation between plasma level of VEGF and the level of alpha fetoprotein (alpha-FP) (r = 0.068, P = 0.658) and weakly correlated with the number of platelets (r = 0.312, P = 0.038). P-VEGF levels increased significantly and reached the peak value on the first day after TACE, and then decreased gradually. The change rate of P-VEGF concentration (one month post-TACE/pre-TACEX100%) was correlated with the retention rate of lipiodol oil (r s = 0.494, P = 0.001) and the tumor volume change (r s = 0.340, P = 0.034). The patients who achieved a partial or complete response to TACE therapy showed significantly less pre-treatment P-VEGF than those nonresponders (P = 0.025). A high pre-therapeutic P-VEGF level was associated with poor response to treatment (P = 0.018). CONCLUSION: A high pre-treatment P-VEGF level is a useful marker for tumor progression, especially for vascular invasion. TACE increases the level of P-VEGF only temporarily which may be associated with tumor ischemia. P-VEGF may be useful in predicting treatment response, monitoring disease course after TACE and judging the effect of different TACE regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B., & Leung, D. W. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-12-1806 · Cited by 1,365
Möhle, R., Green, D., Moore, M. A. S., Nachman, R. L., & Rafii, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.663 · Cited by 713
Platelet: transporter of vascular endothelial growth factor.
Verheul, H. M. W., Hoekman, K., Bakker, S., Eekman, C., Folman, C. C., Broxterman, H. J., & Pinedo, H. M. (1997) · PubMed · Cited by 428
Expression of vascular endothelial growth factor in human hepatocellular carcinoma
Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., & Kojiro, M. (1998) · Hepatology · doi:10.1002/hep.510280111 · Cited by 397
Kraft, A., Weindel, K., Ochs, A., Marth, C., Zmija, J., Schumacher, P., Unger, C., Marm�, D., & Gastl, G. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990101)85:1<178::aid-cncr25>3.0.co;2-7 · Cited by 372
Involvement of platelets in tumour angiogenesis?
Pinedo, H., Verheul, H., D'Amato, R., & Folkman, J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05095-8 · Cited by 358
Pitfalls in the Measurement of Circulating Vascular Endothelial Growth Factor
Jelkmann, W. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.617 · Cited by 322
Mechanism and its regulation of tumor-induced angiogenesis
Gupta, M. K. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i6.1144 · Cited by 294
Dirix, L., Vermeulen, P., Pawinski, A., Prové, A., Benoy, I., De Pooter, C., Martin, M., & Van Oosterom, A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.368 · Cited by 272
Salven, P., Teerenhovi, L., & Joensuu, H. (1997) · Blood · doi:10.1182/blood.v90.8.3167 · Cited by 249
Yamamoto, Y., Toi, M., Kondo, S., Matsumoto, T., Suzuki, H., Kitamura, M., Tsuruta, K., Taniguchi, T., Okamoto, A., Mori, T., et al. (1996) · PubMed · Cited by 244
Poon, R. T.-P., Ng, I. O.-L., Lau, C., Zhu, L.-X., Yu, W.-C., Lo, C.-M., Fan, S.-T., & Wong, J. (2001) · Annals of Surgery · doi:10.1097/00000658-200102000-00012 · Cited by 240
Poon, R. T. P., Lau, C. P.-Y., Ho, J. W., Yu, W.-C., Fan, S.-T., & Wong, J. (2003) · PubMed · Cited by 203
Kondo, S., Asano, M., Matsuo, K., Ohmori, I., & Suzuki, H. (1994) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(94)90016-7 · Cited by 191
Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer
Hyodo, I., Doi, T., Endo, H., Hosokawa, Y., Nishikawa, Y., Tanimizu, M., Jinno, K., & Kotani, Y. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00282-2 · Cited by 175
Lladó, L., Virgili, J., Figueras, J., Valls, C., Domínguez, J., Rafecas, A., Torras, J., Fabregat, J., Guardiola, J., & Jaurrieta, E. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000101)88:1<50::aid-cncr8>3.0.co;2-i · Cited by 174
Jin-no, K., Tanimizu, M., Hyodo, I., Nishikawa, Y., Hosokawa, Y., Doi, T., Endo, H., Yamashita, T., & Okada, Y. (1998) · Journal of Gastroenterology · doi:10.1007/s005350050099 · Cited by 126
Lee, J. K., Hong, Y. J., Han, C. J., Hwang, D. Y., & Hong, S. I. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.1.149 · Cited by 96
Elevated levels of angiogenic cytokines in the plasma of cancer patients
Fuhrmann‐Benzakein, E., Ma, M. N., Rubbia‐Brandt, L., Mentha, G., Ruefenacht, D., Sappino, A., & Pepper, M. S. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000101)85:1<40::aid-ijc7>3.0.co;2-l · Cited by 87
Serum Vascular Endothelial Growth Factor Levels in Various Liver Diseases
Akiyoshi, F., Sata, M., Suzuki, H., Uchimura, Y., Mitsuyama, K., Matsuo, K., & Tanikawa, K. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018863718430 · Cited by 71
Kirsch, M., Schackert, G., & Black, P. M. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_17 · Cited by 70
Blood flow influences vascular growth during tumour angiogenesis
Nasu, R., Kimura, H., Akagi, K., Murata, T., & Tanaka, Y. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690125 · Cited by 49
Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma.
Zhao, J., Hu, J., Cai, J., Yang, X., & Yang, Z. (2003) · PubMed · Cited by 43
Cited by
Kudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., Nojiri, S., Hino, K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318934 · Cited by 721
Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
Raoul, J.-L., Sangro, B., Forner, A., Mazzaferro, V., Piscaglia, F., Bolondi, L., & Lencioni, R. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.006 · Cited by 537
Local-Regional Treatment of Hepatocellular Carcinoma
Lencioni, R., & Crocetti, L. (2012) · Radiology · doi:10.1148/radiol.11110144 · Cited by 514
Metadata
- Authors
- Li, X.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2004
- Volume
- 10
- Issue
- 19
- Pages
- 2878
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W23438228
- Cited by
- 290
- References
- 24
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.